Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, could also represent a future therapeutic option for PCOS, given its very encouraging results in trials primarily focused on obesity and diabetes. This evidence concerns the gene GCG and polycystic ovary syndrome.